More about

Dapagliflozin

News
January 23, 2025
2 min read
Save

ACC announces lineup of 2025 Scientific Session late-breakers

ACC announces lineup of 2025 Scientific Session late-breakers

The American College of Cardiology announced the late-breaking science lineup for its Scientific Session to be held March 29-31 in Chicago and online.

News
October 22, 2024
2 min read
Save

Sodium-glucose inhibitor use in PAH may have mortality benefit

Sodium-glucose inhibitor use in PAH may have mortality benefit

BOSTON — Fewer patients with pulmonary arterial hypertension died at three time points with use of a sodium-glucose cotransporter-2 inhibitor, according to data presented at the CHEST Annual Meeting.

News
August 15, 2024
4 min read
Save

Medicare announces price cuts for 10 drugs in first round of drug price negotiations

Medicare announces price cuts for 10 drugs in first round of drug price negotiations

The Centers for Medicare & Medicaid Services announced lower Medicare Part D prices for 10 drugs that will take effect in 2026, according to a press release.

News
June 19, 2024
2 min read
Save

Top in endocrinology: New OTC glucose monitors; exposure to endocrine-disrupting chemicals

Top in endocrinology: New OTC glucose monitors; exposure to endocrine-disrupting chemicals

The FDA recently cleared two over-the-counter continuous glucose monitoring systems, one for adults with type 2 diabetes who do not use insulin and another for adults without diabetes who are looking to improve overall health and wellness.

News
June 13, 2024
1 min read
Save

FDA approves dapagliflozin for children and adolescents with type 2 diabetes

FDA approves dapagliflozin for children and adolescents with type 2 diabetes

The FDA approved the SGLT2 inhibitor dapagliflozin to improve glycemic control among children and adolescents aged 10 years and older with type 2 diabetes, according to an industry press release.

Learn the Heart

Part of the Healio Network

Sodium-Glucose Transporter 2 (SGLT2) Inhibitors Topic Review

As a class, sodium–glucose transporter 2 inhibitors are novel drugs initially developed for glycemic control in patients with type 2 diabetes. [Cowie MR, et al. Nat Rev Cardiol. 2020;1a]

News
April 01, 2024
3 min read
Save

Dapagliflozin reduces diuretic doses, daily uptitrations and hospital stay for acute HF

Dapagliflozin reduces diuretic doses, daily uptitrations and hospital stay for acute HF

Despite dapagliflozin not improving diuretic efficiency in the setting of acute HF hospitalization, it was associated with fewer diuretic doses to achieve the same weight change as usual care and shorter hospital stay, researchers reported.

News
January 24, 2024
2 min read
Save

Mortality benefit derived from SGLT2 inhibition could extend to HF with improved EF

Mortality benefit derived from SGLT2 inhibition could extend to HF with improved EF

Dapagliflozin plus guideline-directed medical therapy may reduce CV death in patients with HF with improved ejection fraction by lowering risk for sudden death, researchers reported.

News
January 02, 2024
3 min read
Save

Top cardiology news in 2023: A year of firsts for CVD treatments, procedures, devices

Top cardiology news in 2023: A year of firsts for CVD treatments, procedures, devices

Healio | Cardiology Today compiled a list of some of the most important news in cardiology from 2023.

News
November 12, 2023
3 min read
Save

Women at significant risk for urinary, genital infections while using SGLT2i

Women at significant risk for urinary, genital infections while using SGLT2i

SAN DIEGO — Women with autoimmune and rheumatic conditions are at a significant risk for adverse events during treatment with sodium glucose cotransporter 2 inhibitors, according to data presented at ACR Convergence 2023.

View more